A surgical robot can work flawlessly in the lab and still fail its deployment test — on the network, in the hospital, in the workflow. Remedy Robotics' N1 steers a flexible catheter through blood vessels, and in October 2025 the company announced the world's first fully remote neurointerventional procedures: operating from St. Joseph's Health Centre, surgeon Vitor Mendes Pereira worked on patients at St. Michael's Hospital across Toronto, with no bedside interventionist S2. IEEE Spectrum's November 16, 2026 feature adds the fine print: the ten Toronto patients had consented to nonemergency procedures recording angiograms inside their blood vessels — not acute stroke thrombectomies S1.

Latency Is a Budget With a Tripwire

Remedy targets a round-trip latency of no more than 150 milliseconds — just under the average human reaction time of 200 — and whenever latency rises above that threshold, the system pauses all surgical action. That 150 ms figure is a design target and a tripwire, not a certified safe zone: experts usually consider around 100 milliseconds the safe threshold, and University of Washington research cited by Spectrum found many rural communities — and even most countries — struggle to meet even that S1.

Two softer findings matter as much. Japanese researchers who analyzed five years of surgical simulations found surgeons adapting to lag by pausing and moving more slowly; Remedy reports its operators are "quite resilient to latency." And vascular work is forgiving: if the link drops while a catheter sits inside a vessel, the operation can pause in place without damage. For any teleoperated robot, that is a three-line checklist — define a latency budget, enforce an automatic safe state at the limit, and pick first applications where a freeze is not a crash.

Site Selection Beats the Showcase

The access problem Remedy targets is real. Only about one in ten patients eligible for thrombectomy receives one, one in five Americans lives more than an hour from a hospital offering the procedure, and Alaska's only two thrombectomy centers are both in Anchorage. But Spectrum's reporting is blunt about the irony: the places most needing remote surgery lack not just bandwidth but neurologists, catheterization teams, CT scanners and specialized ICUs — what UW researcher Mike Teodorescu calls "an infrastructure problem" S1. The realistic beachhead is the medium-size regional hospital that already has the support stack and patient volume but not 24-hour specialists. Industrial deployments rhyme: audit a site's staffing, spares, connectivity and escalation paths before auditing the robot.

Funded, Not Shipped

Remedy raised a $62 million Series B announced November 16, 2026, led by DCVC with UC Investments participating, earmarked for a planned pivotal trial across the UC network and a push toward FDA approval for neurovascular intervention. The release is equally explicit: the N1 System is under development, not available for sale or clinical use in any jurisdiction S3. The roadmap matches — on-site elective procedures such as unruptured aneurysms first, remote surgeries in Australia or the UC system near the end of 2027 S1. Cofounder Jake Sganga's rule applies to any remote-capable machine: "solve a meaningful problem on-premise," otherwise "doctors simply won't use the system" and nobody builds the expertise to operate remotely. Beyond one-time demonstrations, no robotics company has earned full regulatory approval for telesurgery, and no US patient has been operated on remotely.

So the robot is not ready — and the company says so plainly. What exists today is the deployment contract: latency budget, enforced pause, site audit, on-premise adoption first. That contract, not the catheter, is what the next two years will prove.

Sources and editorial method

This AI-assisted report synthesizes the sources below. Automated source checking is not independent human verification; follow the original reporting for context and updates.

Common questions

What is Remedy's 150 ms latency threshold?

Per IEEE Spectrum, Remedy's N1 targets a round-trip latency of no more than 150 milliseconds and pauses all surgical action above it. It is a design tripwire, not a safety proof: experts usually consider about 100 milliseconds safe, and many rural networks struggle to hold even that.

Is Remedy's N1 available for clinical use?

No. The company's November 16, 2026 funding release states the N1 System is under development and not available for sale or clinical use in any jurisdiction. First trials are on-site elective procedures, with remote surgeries planned near the end of 2027; no US patient has been operated on remotely.